Noninvasive mechanical ventilation with average volume assured pressure support (AVAPS) in patients with chronic obstructive pulmonary disease and hypercapnic encephalopathy by Killen Harold Briones Claudett et al.
Briones Claudett et al. BMC Pulmonary Medicine 2013, 13:12
http://www.biomedcentral.com/1471-2466/13/12RESEARCH ARTICLE Open AccessNoninvasive mechanical ventilation with average
volume assured pressure support (AVAPS) in
patients with chronic obstructive pulmonary
disease and hypercapnic encephalopathy
Killen Harold Briones Claudett1,2,3*, Monica Briones Claudett4, Miguel Chung Sang Wong5,
Alberto Nuques Martinez6, Ricardo Soto Espinoza6, Mayra Montalvo7, Antonio Esquinas Rodriguez8,
Gumersindo Gonzalez Diaz8 and Michelle Grunauer Andrade7Abstract
Background: Non-invasive mechanical ventilation (NIV) in patients with acute respiratory failure has been
traditionally determined based on clinical assessment and changes in blood gases, with NIV support pressures
manually adjusted by an operator. Bilevel positive airway pressure-spontaneous/timed (BiPAP S/T) with average
volume assured pressure support (AVAPS) uses a fixed tidal volume that automatically adjusts to a patient’s needs.
Our study assessed the use of BiPAP S/T with AVAPS in patients with chronic obstructive pulmonary disease (COPD)
and hypercapnic encephalopathy as compared to BiPAP S/T alone, upon immediate arrival in the Emergency-ICU.
Methods: We carried out a prospective interventional match-controlled study in Guayaquil, Ecuador. A total of 22
patients were analyzed. Eleven with COPD exacerbations and hypercapnic encephalopathy with a Glasgow Coma
Scale (GCS) <10 and a pH of 7.25-7.35 were assigned to receive NIV via BiPAP S/T with AVAPS. Eleven patients were
selected as paired controls for the initial group by physicians who were unfamiliar with our study, and these
patients were administered BiPAP S/T. Arterial blood gases, GCS, vital signs, and ventilatory parameters were then
measured and compared between the two groups.
Results: We observed statistically significant differences in favor of the BiPAP S/T + AVAPS group in GCS
(P = .00001), pCO2 (P = .03) and maximum inspiratory positive airway pressure (IPAP) (P = .005), among others.
However, no significant differences in terms of length of stay or days on NIV were observed.
Conclusions: BiPAP S/T with AVAPS facilitates rapid recovery of consciousness when compared to traditional BiPAP
S/T in patients with chronic obstructive pulmonary disease and hypercapnic encephalopathy.
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Noninvasive mechanical ventilation (NIV) is used in pa-
tients with acute respiratory failure for several different
etiologies [1]. The heterogeneity of different patient
groups leads to varying levels of success, with the best
results produced in patients with infectious exacerba-
tions of COPD and congestive heart failure [2-4]. When
NIV is initiated in patients with acute respiratory failure
due to infectious exacerbations of COPD, ventilatory pa-
rameters are typically determined based on clinical as-
sessment and changes in blood gases. In this manner,
NIV support pressures are manually adjusted by an oper-
ator [5].
One of the limitations of traditional NIV is altered
levels of consciousness. However, under certain circum-
stances, especially those produced by hypercapnic
conditions [6-8], traditional NIV has produced very
favorable results, even in patients with hypercapnic
coma [9].
Patients with infectious exacerbations of COPD have
obstruction, hyperinflation, air trapping, and increased
respiratory effort and central respiratory drive. In par-
ticular, blood pCO2 increases, which, due to its high
lipid solubility, readily crosses the blood–brain barrier,
provoking acidosis in the cerebrospinal fluid and cere-
bral interstitial tissue [8-13].
Previous studies that recommend the use of NIV in
patients with altered consciousness report a rapid re-
covery as soon as the ventilatory strategy is established,
and most recommend early intubation and suspen-
sion of treatment if consciousness does not quickly
normalize [9,10]. Altered levels of consciousness can be
assessed using the Glasgow Coma Scale (GCS) [14,15],
the encephalopathy scoring [16], and the Kelly-Matthay
Scale (KMS) [17]. Although KMS is specifically
designed to assess patients with neurological disorders
on NIV, it is not commonly used in the emergency unit/
ICU.
Bilevel positive airway pressure-spontaneous/timed
(BiPAP S/T) with average volume assured pressure sup-
port (AVAPS) allows for setting a fixed tidal volume,
and the system output automatically adjusts based
on variations in inspiratory pressure to ensure the
predetermined target value. Its long-term benefits have
been demonstrated in patients with chronic respira-
tory failure, obstructive sleep apnea, and alveolar
hypoventilation syndrome [18-20].
We designed this study to assess the use of BiPAP S/T
with AVAPS as a ventilatory strategy in patients with
chronic obstructive pulmonary disease (COPD) and hy-
percapnic encephalopathy (GCS < 10) and to compare
these results with those from patients treated with
BiPAP S/T alone, upon immediate arrival in the emer-
gency department/ICU.Methods
Patients
All patients were admitted between February 2009 and
September 2011, and permission was obtained from pa-
tients or their proxies if patients were unable to answer
for themselves. The study was approved by the academic
and ethics committee of the School of Medicine of the
Universidad San Francisco de Quito. Three hospitals in
Guayaquil, Ecuador participated in the study: Hospital
Militar, Clinica Panamericana, and Clinica Santa Maria.
A total of 22 patients were recruited for NIV and divided
into two groups of 11.Treatment group assignments
11 patients with infectious exacerbations of COPD and
hypercapnic encephalopathy with GCS < 10 were desig-
nated to receive BiPAP S/T with AVAPS.
The control group was then selected from patients in
the emergency unit with infectious exacerbations of
COPD and encephalopathy (GCS < 10). Patients were
treated immediately and referred to us by doctors who
were unaware of the study. Each patient was treated
with NIV and was selected according to: APACHE II
score within 4 points, age within 10 points, pH
within 0.04, GCS within 2 points, and BMI within 2
points.Noninvasive mechanical ventilation: BiPAP S/T with
AVAPS
Ventilatory parameters were initially programmed in the
BiPAP S/T mode and AVAPS with an inspiratory posi-
tive airway pressure (IPAP) maximum programmed into
the device of 26 cmH2O, to IPAP minimum pro-
grammed value of 12 cmH2O and an expiratory positive
airway pressure (EPAP) of 6 cmH2O. The programmed
tidal volume was at 8 to 12 ml/kg of IBW, and once the
patient reached clinical stability and sensory, the target
Vt in our patients were reprogrammed to 6–8 ml/kg/
weight according to manufacturer's specifications, the
decision was made by the expert physician in charge of
patient case dependent, respiratory rate was 15 breaths/
min, rise time set at 300–400 ms and inspiratory time
was at a minimum of 0.6 s. Were given supplements O2
via an adapter circuit close to the facemask in order to
maintain SaO2 above 90%. Patients were maintained on
continuous NIV initially.
Maximum IPAP received delivered, exhaled tidal vol-
ume (EVT), Vmin, and leaks were monitored through
the ventilator software. We used BiPAP Synchrony with
AVAPS and Autotrak (Respironics Inc., Murrysville,
Pennsylvania, USA) and a Mirage IV series facemask
(Resmed).
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Arterial blood gases were measured at initial values and
after 1 hour, 3 hours, 12 hours and then every 24 hours
during NIV; the patient was assessed by a respiratory
therapist under close supervision of a physician trained
in NIV. Mask use, complications, and tolerance were
also assessed.
Disease severity was assessed using the APACHE II
score and GCS to determine the patient's level of con-
sciousness. Maximum Vt, maximum IPAP, EVT, Vmin,
leaks, respiratory rate, heart rate, systolic blood pressure,
diastolic blood pressure, and IPAP were measured upon
hospitalization, after 1 hour, 3 hours, and 12 hours, and
then every 24 hours during NIV.
Exclusion criteria included facial deformity, obstruc-
tion in the upper airway from surgery or trauma,
alterations of the central nervous system not related
to hypercapnic encephalopathy, cardiogenic pulmonary
edema, pneumothorax, pulmonary thromboembolism,
hemoptysis or septic shock, emergency intubation due
to cardiopulmonary arrest, and hemodynamic instability
with systolic pressure below 80 mmHg.Discontinuation of NIV
Treatment with NIV was initially used on a continuous
regimen based on patient tolerance and after norma-
lization of arterial pH > 7.35 ventilation was given in
3-hour blocks. The weaning process was initiated when
clinical stability was achieved, which was defined as re-
spiratory rate less than 24 breaths/min, a heart rate of 90
beats/min, and improved awareness and compensation
from normalized pH values, with adequate SaO2 in ambi-
ent air and a low percentage of inspired O2 (3 liters). Once
the patient remained stable, NIV was discontinued.Control group ventilation parameters: BiPAP S/T
Ventilatory parameters were initially programmed in
BiPAP S/T mode. IPAP was programmed at 12 cmH2O,
EPAP was programmed at 6 cmH2O. Respiratory rate
was set at 15 breaths/min, rise time set at 300–400 ms,
and inspiratory time was at a minimum of 0.6 s. Progres-
sively increased levels were IPAP in increments of 2
cmH2O according to the discretion of the attending
physician. Supplements were added O2 via an adapter
circuit close to the facemask to maintain SaO2 above
90%. Patients were maintained on continuous NIV ini-
tially until normalized blood pH ( > 7.35). We monitored
EVT, Vmin, and leakage. We used BiPAP Synchrony and
Autotrak (Respironics Inc.), and two types of facemasks:
Mirage IV series mask (Resmed) and Series II full
facemask (Respironics). We monitored EVT, Vmin, and
leakage in order to program inspiratory pressure Levels
and adjust the mask.In addition to ventilatory support, both groups received
bronchodilators, intravenous corticosteroids, and anti-
biotic therapy consisting of beta-lactam (piperacillin/
tazobactan at 4.5 g IV every 6 hours) in combination with
a new fluoroquinolone (Levofloxacin 500 mg IV daily).
Primary analysis: level of consciousness (Glasgow
Coma Scale score). Secondary analysis: duration of
mechanical ventilation, hospital stay, and progression
(exhaled tidal volume, inspiratory pressure, and arterial
blood gases).
Statistical analysis
All data were expressed as mean ± standard deviation
(SD) for continuous variables and as percentages for cat-
egorical variables. Continuous variables with normal dis-
tribution were examined using the Kolmogorov-Smirnov
test, and were compared using Student's t-test. For cat-
egorical variables, χ2 or Fisher's exact tests were used as
appropriate. We used analysis of variance (ANOVA)
with repeated measures to compare the ability of differ-
ent variables (pH, pCO2, HCO3, heart rate, respiratory
rate, systolic blood pressure, diastolic blood pressure,
EVT, Vmin, leaks, maximum programmed IPAP, and
GCS) to predict the outcome of therapy in experimental
and control patients. A P value <.05 was considered sta-
tistically significant.
Results
A total of 22 patients were analyzed: 11 in the control
group (BiPAP S/T) and 11 in the experimental group
(BiPAP S/T with AVAPS). The mean age of all patients
was 78.68 ± 10.42 years, mean APACHE II score was
18.50 ± 2.56, 9 patients were women (40.9%) and 13
were men (59.1%). Four patients were diagnosed with
COPD with pneumonia (18.2%) and 18 were diagnosed
with infectious exacerbations of COPD (81.3%). Sixteen
patients (73.8%) received NIV in the emergency and
ICU. There were no statistically significant differences
between the two groups in terms of BMI, age, APACHE
II score, or initial GCS score (Table 1). One patient
(4.5%) used a Respironics full face mask, and the other
21 patients (95.5%) used the Mirage IV series (Resmed).
In patients undergoing NIV with BiPAP S/T and AVAPS,
the programmed tidal volume on AVAPS was 622.73 ±
81.74 ml/kg (range: 500–700), with a programmed Vt/kg
of 10.26 ± 2.23 ml (range 7.89- 11,83). The programmed
maximum IPAP values (BiPAP S/T with AVAPS) were:
21.36 ± 3.04 cmH2O (initial), 20.82 ± 3.19 cmH2O (1
hour), 19.36 ± 3.80 cmH2O (3 hours), and 19.55 ± 3.45
cmH2O (12 hours). The ANOVA analysis revealed statis-
tically significant differences in favor of AVAPS for
pCO2 (P = .03), respiratory rate (P = .01), maximum
IPAP (P = .005), GCS score (P = .00001) (Figure 1), and
EVT (P = .01) (Table 2). However, no significant
Table 1 Initial patient assessment results
NIV study groups (All 22 patients) Mean SD P
BMI BiPAP S/T 26.22 2.87 .99
BiPAP S/T +AVAPS 24.23 2.62
Age (years) BiPAP S/T 77.55 6.49 .10
BiPAP S/T + AVAPS 79.82 13.53
APACHE II BiPAP S/T 18.45 2.50 .86
BiPAP S/T + AVAPS 18.55 2.73
Initial GSC BiPAP S/T 8.36 1.43 1.00
BiPAP S/T + AVAPS 8.36 1.63
Initial pH BiPAP S/T 7.28 0.02 .45
BiPAP S/T + AVAPS 7.29 0.03
*Statistically significant (P value <.05).
A total 22 patients. 11 patients of group BiPAP S/T and 11 patients of group
BiPAP S/T +AVAPS.
Briones Claudett et al. BMC Pulmonary Medicine 2013, 13:12 Page 4 of 7
http://www.biomedcentral.com/1471-2466/13/12differences were observed for length of stay (P = .15) or
duration of NIV (P = .18) (Table 3).Discussion
Our study demonstrates that the addition of AVAPS to
BiPAP S/T in patients with encephalopathy and infec-
tious exacerbations of COPD produces a rapid recovery
of consciousness (GCS), with early improvement of arter-
ial blood gases as compared to conventional ventilation
using solely BiPAP S/T. We observed significantly higher
IPAP values in the BIPAP S/T + AVAPS group than in the
group of patients treated solely with BIPAP S/T.
No studies exist in the medical literature describing
the benefits of using NIV with AVAPS in acute patients.
However, in chronic patients with obstructive sleep
apnea and alveolar hypoventilation syndrome, authors
report a rapid improvement in pCO2 and sleep quality
using this technique [18-20]. Most studies reported in
the literature describing successful use of NIV in hyper-
capnic encephalopathy indicate an improvement in GCS












































Evolution of the G
Figure 1 Describes the evolution of the glasgow coma score in bothvast majority of these are clinical case reports or obser-
vational studies [6-8,21-26].
The goal in our study was, the rapid recovery of con-
sciousness in a group of patients undergoing BIPAP S/T +
AVAPS (target volume), we scheduled a target volume be-
tween (500-700ml) in our patients, with a Vt target aver-
age 10.26 ± 2.23 ml (range 7.89 to 11.83), with peak
inspiratory pressures during therapy programmed to 26,
once the patient achieved clinical stable condition and, in
the target Vt our patients were reprogrammed to 6–8 ml/
kg/ weight according to manufacturer's specifications. The
decision was taken by the expert physician in charge of
patient case-dependent (sensory severity scale or mea-
sured initial Glasgow).
BIPAP mode S/T + AVAPS delivered pressure changes
progressively allowing the patient to conform much bet-
ter to those pressures while the target tidal volume is
reached.
Patients with the acute decompensation of COPD, ac-
companied by an altered mental status require rapid
correction of alveolar hypoventilation which ensure an
adequate tidal volume (minute volume) (volume settings
between 8–12 ml/kg/weight) for rapid dissemination or
carbon monoxide swept cerebrospinal fluid and brain
and its sensory recovery as early as possible.
Studies examining the use of NIV in hypercapnic en-
cephalopathy indicate that various ventilatory modes can
be employed at different pressure levels. Gonzales et al
[6] used BiPAP vision or BiPAP ST-D 30, in which IPAP
levels were initially programmed at 12 cmH2O and in-
creased every 4 hours with an IPAP value in the first
hour of 17 + 2 cmH2O. In our study, patients on BiPAP
S/T with AVAPS had an initial IPAP of 19.82, vs 12.36 in
the control group. BiPAP S/T with AVAPS achieves the
necessary inspiratory pressure level for a predetermined
tidal volume, ensuring optimal pressure for the patient
and facilitating a suitable inspiratory volume; this also
rapidly overcomes alveolar hypoventilation, corrects































lasgow Coma Scale (GSC).
groups.
Table 2 Evolution of blood gases, vital signs, and ventilatory parameters (mean ± SD)
Variables Groups Initial 1 hour 3 hours 12 hours P
GSC BiPAP S/T 8.3 ± 1.4 9.7 ± 2 12 ± 1.5 13 ± 1 .00001*
BiPAP S/T + AVAPS 8.3 ± 1.6 11 ± 1 14.1 ± 0.8 15 ± 0
pH BiPAP S/T 7.28 ± 0.02 7.30 ± 0.05 7.31 ± 0.11 7.32 ± 0.12 .31
BiPAP S/T + AVAPS 7.29 ± 0.03 7.34 ± 0.04 7.37 ± 0.11 7.37 ± 0.08
pCO2 BiPAP S/T 64.8 ± 9.1 58.3 ± 8.7 53.2 ± 9 50.1 ± 6.5 .03*
BiPAP S/T + AVAPS 63 ± 16.3 50.7 ± 11.2 45.4 ± 7.9 43.6 ± 6.5
PO2 BiPAP S/T 66.6 ± 12.7 83.1 ±17.8 75.3 ± 26.7 79.7 ± 16.2 .31
BiPAP S/T + AVAPS 71.5 ± 16.8 78 ± 19.1 87.5 ± 11.5 87.4 ± 18
HCO3 BiPAP S/T 26.9 ± 5.7 24.4 ± 6.3 25.8 ± 4.6 27.1 ± 4.3 .19
BiPAP S/T + AVAPS 24.4 ± 5 22.5 ± 3.5 23.7 ± 5.2 24.6 ± 4.3
Base excess BiPAP S/T 3.3 ± 6.9 0.1 ± 7 10.3 ± 31.7 3.6 ± 4.7 .06
BiPAP S/T + AVAPS −1.8 ± 5.7 2.8 ± 18 5.7 ± 19.8 2.9 ± 9
Systolic blood pressure BiPAP S/TS/T 125.1 ± 10 124.2 ± 12.6 130.4 ± 14.3 130.6 ± 13.8 .29
BiPAP S/T + AVAPS 125.9 ± 17.3 131.1 ± 21.1 129.9 ± 18.4 123.5 ± 16.9
Diastolic blood pressure BiPAP S/T 73.9 ± 9.8 72.2 ± 8.4 71.8 ± 9.4 73.7 ± 10.7 .07
BiPAP S/T + AVAPS 65.5 ± 11.6 69.8 ± 11.6 70.1 ± 11.1 65.9 ± 8.5
Heart rate BiPAP S/T 86.7 ± 9.1 82.1 ± 7.8 80.4 ± 5.8 79.1 ± 5.5 .07
BiPAP S/T + AVAPS 82 ± 10.9 82.5 ± 9.9 72.8 ± 14.1 72. ± 11.2
Respiratory rate BiPAP S/T 27.9 ± 5.6 23.2 ± 3.5 21 ± 2.6 20 ± 1.61 .01*
BiPAP S/T + AVAPS 29 ± 6.9 17.4 ± 3.2 18.5 ± 3.6 19.9 ± 5.1
Maximum delivered IPAP received BiPAP S/T 12.3 ± 0.9 12.6 ± 0.9 14.3 ± 0.8 14.7 ± 1 .005*
BiPAP S/T + AVAPS 19.8 ± 2.2 18.3 ± 2.3 18 ± 2.6 17 ± 2.3
EPAP BiPAP S/T 5.9 ± 0.3 6 ± 0 6 ± 0 6 ± 0 .32
BiPAP S/T + AVAPS 6 ± 0 6 ± 0 5.9 ± 0.3 5.9 ± 0.3
Minute volume BiPAP S/T 8.7 ± 3.1 9.2 ± 2.2 10.8 ± 1.4 10.6 ± 1.4 .17
BiPAP S/T + AVAPS 8.5 ± 2.2 10.5 ± 2.5 11.5 ± 3.1 11.6 ± 1.8
Exhaled tidal volume BiPAP S/T 304 ± 60.6 400.5 ± 73.9 519 ± 61.4 531.1± 63.6 .01*
BiPAP S/T + AVAPS 298.6 ± 54.3 606.3 ± 75.4 626.3 ± 77.6 617.6 ± 77.4
Leak BiPAP S/T 9.3 ± 3.8 21 ± 2 11 ± 3 11 ± 3.4 .20
BiPAP S/T + AVAPS 14 ± 11.2 18.3 ± 3.7 17.5 ± 16 17.5 ± 16
*Statistically significant (P value <.05).
**The ANOVA with repeated measures to compare the ability of different variables the both groups at 1, 3, 12 hours.
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et al. compared manually adjusted pressures with self-
adjusting pressure support in patients with acute respira-
tory failure, which produced a decrease in pCO2 levels
in the latter group [27].Table 3 Duration of hospital stay and time on NIV
Group
Duration of hospital stay (days) BiPAP S/T
BiPAP S/T + AVAPS
Duration of NIV (days) BiPAP S/T
BiPAP S/T + AVAPS
*Statistically significant (P value <.05).Some studies found favorable results in patients using
NIV in hypercapnic encephalopathy reduction in days of
mechanical ventilation [26] reduced risk of nosocomial
infection [28,29] and avoid intubation [30]. Recently, a





Briones Claudett et al. BMC Pulmonary Medicine 2013, 13:12 Page 6 of 7
http://www.biomedcentral.com/1471-2466/13/12endotracheal tube through BiPAP in patients with a mean
GCS of 6, a mean pH of 7.1, and poor management of
Secretions, with a success rate of 85% (17/20) [31].
In our study, initial GCS and pH values were virtually
equal between groups. Secretions were properly man-
aged, which is essential for preventing technique failure
and the need for endotracheal intubation. We observed
a rapid and significant improvement in arterial blood
gases and consciousness (GCS) in both groups; however,
patients treated with BiPAP S/T + AVAPS improved
much faster than patients treated with the conventional
strategy, with a near-complete recovery within 3 hours.
The improvement in the BiPAP S/T AVAPS group was
probably linked to the rapid improvement in EVT and
the fact that, in these patients, IPAP quickly reached the
levels needed for maintaining appropriate tidal volume,
and hypoventilation was corrected with consequent im-
provements in alveolar ventilation.
We observed no complications, gastric distention, or
facial deformities, probably due to the fact that max-
imum system pressures did not surpass 20 cmH2O,
which is the threshold associated with damage to the
upper esophageal sphincter and facial structures [32,33].
Our study has certain limitations, including a small
number of patients, despite the inclusion of three hospi-
tals. In addition, the study was performed by a single re-
search group with a long-term experience in NIV, which
could create problems when extrapolating the results.
Finally, it should be emphasized that our patients had a
mean pH greater than 7.25, whereas other studies of hy-
percapnic encephalopathy have reported lower values.
Other studies have also reported higher levels of pCO2
as causing altered levels of consciousness. The lower
values of pCO2 that we observed could be due to several
reasons. Firstly, some of our patients live at high altitude
places. Gonzalez Garcia et al. [34], showed lower-than
-normal pH and pCO2 values in patients with COPD
undergoing effort or exercise [35]. Secondly, some of
our patients might have had a very low pH with
prolonged base excess and bicarbonate for patients with
COPD. The effects of blood volume, diuretic use, height
and affecting renal bicarbonate reabsorption have not
been assessed [36]. We must also consider that patients
in both groups experienced a rapid improvement in
GCS of 2 points or more within 3 hours of starting treat-
ment; a lack of improvement of 2 points could be a de-
termining factor for rapid endotracheal intubation,
which would obviously constitute an invasive procedure
[34]. Finally, our study involved matched case-controls
without randomization. Despite these limitations, we be-
lieve that this study provides valuable information, as it
confirms the usefulness of NIV in hypercapnic encephal-
opathy, and upholds BiPAP S/T with AVAPS as a strat-
egy that ensures safe and appropriate pressures and tidalvolumes, facilitating a rapid correction of arterial blood
gases, especially pCO2, and thus, minimizing the dele-
terious effects to the brain.
Conclusions
We propose the use of BiPAP S/T with AVAPS as a safe
strategy of noninvasive ventilatory treatment in patients
with exacerbations of COPD and hypercapnic encephal-
opathy (GCS < 10), with the caveat that these patients
should be treated in units with ample experience and
under close surveillance.
Abbreviations
APACHE II: Acute physiology and chronic health evaluation II;
AVAPS: Average volume assured pressure support; BiPAP (S/T): Bilevel
positive airway pressure (spontaneous/timed); EPAP: Expiratory positive
airway pressure; EVT: Exhaled tidal volume; GCS: Glasgow Coma Scale;
IPAP: Inspiratory positive airway pressure; NIV: Noninvasive mechanical
ventilation; pCO2: Partial pressure of carbon dioxide; Vmin: Minute volume;
Vt: Tidal volume; COPD: Chronic obstructive pulmonary disease.
Competing interests
None of the authors have a competing of interests to declare in relation to
this work.
Authors’ contributions
KHBCl: contributed to the study design; data acquisition, analysis, and
interpretation; drafting and revision of the manuscript; and preparation of
the final version of the manuscript submitted. MHBC: contributed to the
study design; analysis, and interpretation; and preparation of the final version
of the manuscript submitted. MCS: contributed to the study design; data
acquisition, analysis and revision of the manuscript. ANM: contributed to the
study design; data acquisition and revision of the manuscript. RSE:
contributed to the study design; data acquisition and revision of the
manuscript. MM: drafting and revision of the manuscript preparation of the
final version of the manuscript submitted. AER: preparation of the final
version of the manuscript submitted. GGD: analysis and preparation of the
final version of the manuscript submitted. MGA: drafting and revision of the
manuscript; preparation of the final version of the manuscript submitted. All
authors read and approved the final manuscript.
Author details
1Pulmonology Department, Military Hospital, Guayaquil, Ecuador.
2Department of Respiratory Medicine, Panamericana Clinic,
Guayaquil, Ecuador. 3Department of Respiratory Medicine – Intensive Care,
Santa Maria Clinic, Guayaquil, Ecuador. 4Department of Pneumology –
Intensive Care, Regional Hospital of Guayaquil, Guayaquil, Ecuador. 5Intensive
Care Medicine, Santa Maria Clinic, Military Hospital, Guayaquil, Ecuador.
6Intensive Care Medicine Panamericana Clinic and Ecuadorian Institute Social
Security (IESS), Guayaquil, Ecuador. 7Universidad San Francisco de Quito,
Quito, Ecuador. 8Intensive Care Unit and Pneumology Services of the
Hospital JM Morales Meseguer, Murcia, Spain.
Received: 29 August 2012 Accepted: 6 March 2013
Published: 12 March 2013
References
1. Meduri GH, Turner RE, Abou-Shala N, Wunderink R, Tolley E: Noninvasive
positive pressure ventilation via face mask. First-line intervention in
patients with acute hypercapnic and hypoxemic respiratory failure.
Chest 1996, 109:179–193.
2. Keenan SP, Sinuff T, Cook DJ, Hill N: Which patients with acute
exacerbation of chronic obstructive pulmonare disease benefit from
noninvasive positive – pressure ventilation? A systematic review of the
literature. Ann Intern Med 2003, 138:861–870.
3. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS: Non-invasive positive
pressure ventilation to treat respiratory failure resulting from
exacerbations of chronic obstructive pulmonary disease: Cochrane
Briones Claudett et al. BMC Pulmonary Medicine 2013, 13:12 Page 7 of 7
http://www.biomedcentral.com/1471-2466/13/12systematic review and meta-analysis. BMJ 2003, 362:1–5. doi:10.1136/
bmj.326.7382.185.
4. Winck JC, Azevedo LF, Costa-Pereira A, Antonelli M, Wyatt JC: Efficacy and
safety of non-invasive ventilation in the treatment of acute cardiogenic
pulmonary edema—a systematic review and meta-analysis. Crit Care
2006, 10:R69.
5. Carlucci A, Delmastro M, Rubini F, Fracchia C, Nava S: Changes in the
practice of non-invasive ventilation in treating COPD patients over 8
years. Intensive Care Med 2003, 29:419–425.
6. Adnet F, Racine SX, Lapostolle F, Cohen Y, Cupa M, Minadeo J: Full reversal
of hypercapnic coma by noninvasive positive pressure ventilation.
Am J Emerg Med 2001, 19:244–246.
7. Diaz GG, Alcaraz AC, Talavera JC, et al: Noninvasive positive-pressure
ventilation to treat hypercapnic coma secondary to respiratory failure.
Chest 2005, 127:952–960.
8. Zhu GF, Zhang W, Zong H, Xu QF, Liang Y: Effectiveness and safety of
noninvasive positive pressure ventilation for severe hypercapnic
encephalopathy due to acute exacerbation of chronic obstructive
pulmonary disease. Chin Med J 2007, 120:2204–2009.
9. Briones K, Briones M, Chung M, et al: Noninvasive mechanical ventilation
in patients with chronic obstructive pulmonary disease and severe
hypercapnic neurological deterioration in the emergency room.
Eur J Emerg Med 2008, 15:127–133.
10. Scala R, Naldi M, Archinucci I, Coniglio G, Nava S: Noninvasive positive
pressure ventilation in patients with acute exacerbation of COPD and
varying levels of consciousness. Chest 2005, 128:1657–1666.
11. Kilburn K: Neurologic manifestations of respiratory failure. Ann Intern Med
1965, 63:919–920.
12. Posner JB, Swanson AG, Plum F: Acid base balance in cerebrospinal fluid.
Arch Neurol 1965, 12:479–496.
13. Meissner HH, Franklin C: Extreme hypercapnia in a fully alert patient.
Chest 1992, 102:1298–1299.
14. Jennett B: Development of Glasgow coma and outcome scales. Nepal J
Neurosci 2005, 2:24–28.
15. Teasdale G, Jennet B: Assessment of coma and impaired consciousness. A
practical scale. Lancet 1974, 2:81–84.
16. Kelly BJ, Matthay MA: Prevalence and severity of neurological dysfunction
in critically ill patients. Influence on need for continued mechanical
ventilation. Chest 1993, 104:1818–18224.
17. Scala R, Naldi M, Coniglio G, Archinucci I: Neurological evaluation in
hypercapnic encephalopathy treated with non-invasive ventilation:
comparison of two scores. Eur Respir J 2007:262s–263s.
18. Storre JH, Seuthe B, Fiechter R, et al: Average volume-assured pressure
support in obesity hypoventilation: a randomized crossover trial. Chest
2006, 130:815–821.
19. Murphy PB, Davidson C, Hind MD, et al: Volume targeted versus pressure
support non-invasive ventilation in patients with super obesity and chronic
respiratory failure: a randomised control ed. Thorax 2012, 67:727–734.
20. Ambrogio C, Lowman X, Kuo M, Malo J, Prasad AR, Parthasarathy S: Sleep
and non-invasive ventilation in patients with chronic respiratory
insufficiency. Intensive Care Med 2009, 35:306–313.
21. Scala R, Archinucci I, Naldi M, et al: Non-invasive nasal ventilation in a
case of hypercapnic coma. Minerva Anestesiol 1997, 63:245–248.
22. Adnet F, Racine SX, Lapostolle F, Cohen Y, Cupa M, Minadeo J: Full reversal
of hypercapnic coma by noninvasive positive pressure ventilation.
Am J Emerg Med 2001, 19:244–246.
23. Scarpazza P, Incorvaia C, di Franco G, et al: Effect of noninvasive
mechanical ventilation in elderly patients with hypercapnic acute-on
-chronic respiratory failure and a do-not-intubate order. Int J Chron
Obstruct Pulmon Dis 2008, 3:797–801.
24. Benhamou D, Girault C, Faure C, Portier F, Muir JF: Nasal mask ventilation
in acute respiratory failure. Experience in elderly patients. Chest 1992,
102:912–917.
25. Dueñas-Pareja Y, Lopez-Martin S, Garcia-Garcia J, et al: Non-invasive
ventilation in patients with severe hypercapnic encephalopathy in a
conventional hospital ward. Arch Bronchoneumol 2002, 38:372–375.
26. Scala R, Nava S, Conti G, et al: Noninvasive versus conventional ventilation
to treat hypercapnic encephalopathy in chronic obstructive pulmonary.
Intensive Care Med 2007, 33:2101–2108.
27. Battisti A, Tassaux D, Bassin D, Jolliet P, et al: Automatic adjustment of
noninvasive pressure support with a bilevel home ventilator in patientswith acute respiratory failure: a feasibility study. Intensive Care Med 2007,
33:632–638.
28. Guerin C, Girard R, Chemorin C, De Varax R, Fournier G: Facial mask
noninvasive mechanical ventilation reduces the incidence of nosocomial
pneumonia. A prospective epidemiological survey from a single ICU.
Intensive Care Med 1997, 23:1024–1032.
29. Nourdine K, Combes P, Carton MJ, Beuret P, Cannamela A, Ducreux JC:
Does noninvasive ventilation reduce the ICU nosocomial infection risk?
A prospective clinical survey. Intensive Care Med 1999, 25:567–573.
30. Scala R, Naldi M, Maccari U: Early fiberoptic bronchoscopy during non-
invasive ventilation in patients with decompensated chronic obstructive
pulmonary disease due to community-acquired pneumonia. Crit Care
2010, 14:80–86.
31. Rawat J, Sindhwani G, Biswas D, Dua R: Role of BiPAP applied through
endotracheal tube in unconscious patients suffering from acute
exacerbation of COPD: a pilot study. Int J Chron Obstruct Pulmon Dis 2012,
7:321–325. doi:10.2147/COPD.S30126. Epub.
32. Tournadre JP, Chassard D, Berrada KR, Bouletreau P: Cricoid cartilage
pressure decreases lower esophageal sphincter tone. Anesthesiology 1997,
86:589–602.
33. Castell JA, Dalton CB, Castell DO: Pharyngeal and upper esophageal
sphincter manometry in humans. Am J Physiol 1990, 258:173–178.
34. Costello R, Deegan P, Fitzpatrick M, McNicholas WT: Reversible hypercapnia in
chronic obstructive pulmonary disease: a distinct pattern of respiratory
failure with a favorable prognosis. Am J Med 1997, 102:239–234.
35. González-García M, Barrero M, Maldonado D: Exercise limitation in patients
with chronic obstructive pulmonary disease at the altitude of Bogota
(2640 m). Breathing pattern and arterial gases at rest and peak exercise.
Arch Bronchoneumol 2004, 40:54–61.
36. de Paula JM P, et al: The importance of identifying the association
between metabolic alkalosis and respiratory acidosis.
Arch Bronchoneumol 2011, 48:65–66.
doi:10.1186/1471-2466-13-12
Cite this article as: Briones Claudett et al.: Noninvasive mechanical
ventilation with average volume assured pressure support (AVAPS) in
patients with chronic obstructive pulmonary disease and hypercapnic
encephalopathy. BMC Pulmonary Medicine 2013 13:12.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
